Major Revision of USP Chapter <1724> Semisolid Drug Products Performance Tests Published for Comment

Recommendation
Tuesday, 17 June 2025 9 .00 - 15.30 h
Suitable analytical methods to assess AAV quality during development and manufacturing
In the current Pharmacopeial Forum, PF 48(3), a major revision of USP general chapter <1724> Semisolid Drug Products—Performance Tests is being proposed. This proposal is based on the version of the chapter official as of August 01, 2013.
The scope of the currently valid chapter is "to provide general information for performance testing of semisolid drug products, various types of equipment employed for such testing, and potential applications of the performance testing". Compared to the currently valid version, the scope of the new draft has been expanded. It also includes in vitro release test (IVRT) as well as in vitro permeation test (IVPT) methods, with discussions on experimental design, method development, and validation.
According to the briefing notes, the proposal further includes "new information on appropriate contexts of use for IVRT and IVPT studies, and a guide for selecting an appropriate test method (IVRT or IVPT) depending upon the goal of the experiment." In addition, the text contains "revise information related to test equipment for IVRT and IVPT studies, with general discussions on setup and qualification considerations for vertical diffusion cells, immersion cells, and flow-through diffusion cells."
The text was also adapted and expanded in other parts. All these changes are noticeable in a more detailed structuring of the subchapters. The chapter is now divided into the following sections:
- Scope
- Introduction
- In vitro release test (IVRT)
- In vitro permeation test (IVPT)
- Equipment
The draft of the revised chapter is available on PF Online. (Please note: a one-time registration is required to access the Pharmacopeial Forum. Comments can be submitted until July 31, 2022.
Related GMP News
11.06.2025USP informs about Monographs affected by the Revision of NMR Chapters <761> and <1761>
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies
15.05.2025Update of USP Chapter <1099> on Content Uniformity in Large Samples
15.05.2025USP Education Webinar on <1058>